Christina Mattina

Assistant Managing Editor at American Journal of Managed Care

Featured in: Favicon

ajmc.com

onclive.com Favicon

oncnursingnews.com Favicon

newsbreak.com Favicon

medicaleconomics.com Favicon

drugtopics.com Favicon

centerforbiosimilars.com Favicon

businessandamerica.com

Articles

Managed Care Reflections: A Q&A With John Michael O’Brien, PharmD, MPH

1 week ago | ajmc.com | Christina Mattina

AJMC: How have the concept of managed care and the conversations around it changed over the past 30 years? O’BRIEN: Over my 30 years in health care, I’ve seen managed care go from being a derogatory term that referred to stinting on care to achieve PMPM [per-member per-month] savings to being a movement that embraced better health, better care, and lower total health care costs.
FDA Approves Nipocalimab for Generalized Myasthenia Gravis

2 weeks ago | ajmc.com | Christina Mattina

The FDA Wednesday approved nipocalimab-aahu (Imaavy; Johnson & Johnson) for the treatment of generalized myasthenia gravis (gMG) in adults and pediatric patients 12 years or older who are anti–acetylcholine receptor (AChR) or anti–muscle-specific kinase (MuSK) antibody positive.1 The approval of the FcRn-blocking monoclonal antibody, which works by reducing immunoglobulin G (IgG), was supported by data from the ongoing Vivacity-MG3 study.
Trump Administration Should Focus on Fixing IRA, 340B: John M. O’Brien, PharmD, MPH

2 weeks ago | ajmc.com | Julia Bonavitacola |Christina Mattina

John Michael O'Brien, PharmD, MPH, president and CEO of the National Pharmaceutical Council (NPC), discussed how the current administration could focus on the Inflation Reduction Act, pharmacy benefit managers (PBMs), and the 340B program to help patients with the rising cost of health care. This transcript was lightly edited for clarity; captions were auto-generated.
Employers Play a Big Part in Future Changes to Managed Care: John M. O'Brien, PharmD, MPH

2 weeks ago | ajmc.com | Julia Bonavitacola |Christina Mattina

John Michael O'Brien, PharmD, MPH, president and CEO of the National Pharmaceutical Council, discussed how managed care will change in the upcoming years, with employers being more engaged in the area than ever before. This transcript has been lightly edited for clarity; captions are auto-generated. TranscriptWhat changes do you see taking place in managed care over the coming years?
Managed Care Has Experienced Numerous Changes Since the First Publication of AJMC®: John Michael O'Brien, PharmD, MPH

3 weeks ago | ajmc.com | Julia Bonavitacola |Christina Mattina

John Michael O'Brien, PharmD, MPH, a member of AJMC’s editorial board and the president and CEO of the National Pharmaceutical Council (NPC), spoke about how he believes managed care has changed since The American Journal of Managed Care® first published in 1995. This transcript has been lightly edited for clarity; captions are auto-generatedTranscriptHow has the concept of managed care and the conversations around it changed over the past 30 years?
ACOs’ Focus on Rooting Out Fraud Aligns With CMS Vision Under Oz

3 weeks ago | ajmc.com | Christina Mattina

First catheters, now skin substitutes—and more areas of anomalous medical billing will continue to pop up, requiring data vigilance and collaboration on the part of accountable care organizations (ACOs), according to speakers at the National Association of ACOs (NAACOS) Spring 2025 Conference. The identification of these areas potentially signaling fraud aligns with the Trump administration’s focus on promoting efficiency and cutting out waste, as described by new CMS Administrator Mehmet Oz, MD.
Managed Care Reflections: A Q&A With Hoangmai H. Pham, MD, MPH

1 month ago | ajmc.com | Hoangmai Pham |Christina Mattina

Am J Manag Care. 2025;31(4):In Press_____AJMC: How has the concept of managed care and the conversations around it changed over the past 30 years? PHAM: On the positive side, it has become a familiar way of life for American consumers, so there isn’t the vilification that had been going on in the 1990s.
MDA Reflects on 75 Years of Research and the Precarious Times Ahead

1 month ago | ajmc.com | Christina Mattina

Neuromuscular disease researchers, clinicians, and advocates gathered to celebrate 75 years of progress at the 2025 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference in Dallas, Texas, but they also noted that these gains could be reversed if cuts to Medicaid and research funding proceed.
STEER Data Open Door to SMA Gene Therapy for Wider Age Range of Children

1 month ago | ajmc.com | Christina Mattina

Results from the phase 3 STEER study of intrathecal onasemnogene abeparvovec showed encouraging efficacy and safety data for children aged 2 to 17 years with spinal muscular atrophy (SMA), paving the way for much broader uptake of this disease-modifying gene therapy.1 The findings were presented in a late-breaking research session of the 2025 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference in Dallas, Texas, held March 16-19, 2025.
Neurologists Share Tips for Securing Patient Access to Gene Therapies

1 month ago | businessandamerica.com | Christina Mattina

Transformative gene therapies for neuromuscular diseases won’t make it into patients’ hands without the tenacious efforts of clinicians, hospital administrators, and other advocates, experts said at a session of the 2025 Muscular Dystrophy Association Clinical & Scientific Conference in Dallas, Texas, as they shared their advice for driving the change to enable patients to receive these advances.